FDAapproval95% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Saptalis Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Antihistamine
- Sub-indication
- General
Related signal: FDA Approves Hydroxyzine Hydrochloride ANDA220271 by Saptalis Pharmaceuticals